Study of occurrence of Multidrug Resistant Escherichia coli Clinical isolates as a result of Extended Spectrum Beta-Lactamase (Esbls) Production


  • Abba, P. O
  • Akor, J. O



Antibiotic resistance, ESBL, Escherichia coli, Beta-lactamase, Benue


Resistance to antibiotics by microorganisms has increased dramatically in the past few years. Resistance to third-generation cephalosporins and other classes of antibiotics is attributed to the production of beta-lactamase genes located on mobile genetic elements, which facilitate their transfer between different species. This study was undertaken to determine the presence of ESBLs in 400 isolates of Escherichia coli obtained from various clinical specimens (urine, stool, blood, wound swabs, sputum and throat swabs) collected from 216 female and 184 male patients attending various health facilities in Makurdi, Benue State, Nigeria; and to relate ESBL production with antibiotic resistance. Antibiotic susceptibility test using penicillin, ceftriaxone, ceftazidime, cefuroxime, cefotaxime, amoxicillin and clavulanic acid, gentamycin, chloramphenicol and imipenem antibiotic discs sourced from OXOID, USA was carried out, using NCCLS guidelines on the isolates. The presence of ESBLs was determined using the Double Disc Synergy (DDST) test. The isolates showed the highest resistance to penicillin 392(98%) producing 62(15.8%) ESBLs. Only 8 (2%) isolates were susceptible to penicillin. This was closely followed by resistance to ceftriaxone (385; 96.3%), producing 62(16.1%) ESBLs. The isolates were also resistant to other classes of antibiotics:  aminoglycosides (gentamycin) 331(82.7%), carbapenem, imipenem 2(0.5%) which was the least. Three hundred and ninety-eight (99.5%) of the isolates were susceptible to imipenem. Isolates from blood specimens (26.3%; n=5) harboured the highest percentage of ESBLs, followed by isolates from wound swab specimens (17.3%; n=9). The study showed moderate production of ESBLs resulting in multiple antibiotic resistance.


D. M. Livermore, “Fourteen years in resistance”, International Journal of Antimicrobial Agents, 2012 (39): 283-294.

D.L. Paterson and R.A. Bonomo, “Extended spectrum beta-lactamse: a clinical up date”, Clinical Microbio. Rev., 2005, 18:657-686.

E. Sturenburg, and D. Mack, “Extended Spectrum Beta- lactamases: implications for the clinical microbiology laboratory”, Journal of Infection, 2003, 47: 273 – 95.

E. Lautenbach, J. B. Patel, W. B. Buker, P. H. Edelstein and N. O. Fishman,

“Extended – spectrum Beta- lactamases – producing Escherichia coli and Klebsiella pneumoniae. Risk factors for infection and impact on resistance of outcome” Clinical Infectious Disease, 2001, 32: 1162 – 1171.

D. Szabo, I. Bais, and F. Rozgomyi, “Extended spectrum b-lactamase: an actual problem of hospital microbiology (a review)”, Acta Microbiol. Immunol. Hung. 1997, 44: 309–325.

D.O. Ogbolu, O.A Daini, A. Ogunledun, A.O. Alli, and M.A. Webber, “High levels of multidrug resistance in clinical isolates of Gram-negative pathogens from Nigeria”, International Journal of Antimicrobial Agents, Elsevier, 2010, 37 (1): 62.

K.I. Onyedibe, E.O. Shobowale, M.O. Okolo, M.O. Iroezindu, T.O. Afolaranmi, F.O. Nwaokorie, S.O. Opajobi, S.E.Isa, and D.Z. Egah, “Low Prevalence of Carbapenem Resistance in Clinical Isolates of Extended Spectrum Beta Lactamase (ESBL) Producing Escherichia coli in North Central, Nigeria”, Advances in Infectious Diseases, 2018, (8): 109-120.

P. O. Abba, E. U. Umeh, G. M. Gberikon, and E. B. Agbo, “Prevalence of Extended Spectrum Beta-Lactamase-Producing Escherichia coli Isolated from Selected Health Facilities in Makurdi. International Journal of Research and Innovation in Applied Science”, 2019, 4(7): 2454-6194

K. E. Kollef, G. E. Schramm, A. R. Wills, R. M. Reichley, S. T. Micek, and H. M. Kollef, “Predictors of 30-day mortality and hospital costs in patients with ventilator associated pneumonia attributed to potentially antibiotic-resistant gram negative bacteria” Chest Journal, 2008, 134(2):281–7.

M. S. Islam, and M.A. Yusuf, “Extended spectrum beta lactamase producing uropathogenic E. coli infection in Dhaka Bangladesh”, Journal 0f Bacteriology Research, 2014, 7: 1-7

E. E. Okwori, S.I. Nwadioha, E.O.P. Nwokedi, M. Odimayo, and G.T.A. Jombo, “Bacterial pathogens and their antibiotic susceptibility pattern in Idoma Community, Benue state of Nigeria”, International Journal of Infectious Diseases, 2011, 1(5): 6-8

S. Hassan, S. A. Jamal, and M. Kamal, “Occurrence of multidrug resistant and ESBL-producing E. coli causing urinary tract infections”, Australian Journal of Basic and Applied Sciences, 2011, 7: 39-43.

R. Farzana, S.M. Shamsuzzaman, K. Z. Mamun, and P. Shears, “Antimicrobial susceptibility pattern of extended spectrum b-lactamase producing gram-negative bacteria isolated from wound and urine in a Tertiary care Hospital, Dhaka city, Bangladesh”, Southeast Asian Journal of Tropical Medicine and Public Health, 2013, 44(1):96-103

G. A. Jacoby, and L. Sutton, “Beta-lactamases and Betalactam resistance in Escherichia coli”, Antimicrobial Agents and Chemotherapy, 1985, 28(5): 703-705.

I.R Iroha, E.S. Amadi, A.E. Oji, A.C. Nwuzo and P.C. Ejike-Ugwu, “Detection of Plasmid Borne ESBL Enzymes from Blood and Urine Isolates of Gram Negative Bacteria from a University Teaching Hospital in Nigeria”, Current Research in Bacteriology, 2010, (3): 77-83.

J. D. Knudsen, and S. E. Andersen, “A multi-disciplinary intervention to reduce infections of ESBL- and AmpC-producing Gram negative bacteria at a university hospital”, PLOS ONE; 2014, 9 (1): 86457.

I.N. Okeke, A. Lamikaran, and R. Edelman, “Socio-economic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries”, Emerging Infectious Disease, 19995, (1): 18 – 27.



How to Cite

Abba, P. O, & Akor, J. O. (2020). Study of occurrence of Multidrug Resistant Escherichia coli Clinical isolates as a result of Extended Spectrum Beta-Lactamase (Esbls) Production. International Journal of Advances in Scientific Research and Engineering, IJASRE (ISSN: 2454 - 8006), 6(6), 1-6.